Shinder Brian M, Shupe Adam, Lee Geun Taek, Stein Mark N, Kim Isaac Y, Singer Eric A
Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.
Division of Medical Oncology, Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.
Transl Cancer Res. 2018 Aug;7(4):1135-1142. doi: 10.21037/tcr.2018.03.41.
As we learn more about the molecular biology of genitourinary malignancies, novel therapeutic strategies can be developed. This is especially crucial for prostate, renal, and bladder cancer, where mortality rates remain high especially in advanced disease states. The androgen signaling axis and the androgen receptor (AR) are areas that are actively being explored for their role in these diseases. Although long been associated with prostate cancer development and progression, the role of AR in renal cell carcinoma (RCC) and bladder cancer is becoming recognized as well. This review will highlight the current research into the role of the androgen signaling axis in genitourinary malignancies and how this pathway is being used to expand our therapeutic armamentarium.
随着我们对泌尿生殖系统恶性肿瘤分子生物学的了解不断深入，可以开发出新的治疗策略。这对于前列腺癌、肾癌和膀胱癌尤为关键，因为这些癌症的死亡率仍然很高，尤其是在疾病晚期。雄激素信号轴和雄激素受体（AR）是目前正在积极探索其在这些疾病中作用的领域。尽管长期以来一直认为AR与前列腺癌的发生和发展有关，但AR在肾细胞癌（RCC）和膀胱癌中的作用也逐渐得到认可。本综述将重点介绍目前关于雄激素信号轴在泌尿生殖系统恶性肿瘤中作用的研究，以及该通路如何被用于扩展我们的治疗手段。
